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ABSTRACT 
Sjögren’s syndrome (SS) and systemic lupus erythematosus (SLE) are systemic rheumatic 
autoimmune diseases having a major impact on patient’s wellbeing. Besides fatigue, pain 
and direct damage to exocrine glands in SS, and various target organs, such as skin, joints, 
kidneys and brain in SLE, these diseases confer an increased risk of lymphoma 
development and can cause an autoimmune condition in the foetus of pregnant patients, 
termed neonatal lupus. 
Several cell types and cytokines contribute to the autoimmune process, with central roles 
for B cells and autoantibodies. Mature B cells are attracted to the sites of inflammation by 
chemokine CXCR5. Recent studies identified CXCR5 as a susceptibility gene in SS, and a 
decrease in expression of CXCR5 on circulating B cells in SS patients, however, the link 
between the polymorphisms in the CXCR5 locus and B cell trafficking wasn’t addressed. 
We therefore explored the expression of the chemokine on lymphocytes in peripheral blood 
and minor salivary glands in SS patients. Confirming the previous findings, our results 
demonstrate reduced CXCR5 expression in circulating B cell pool, coinciding with the 
accumulation of CXCR5-positive cells in the salivary glands of the patients. We conclude 
that the observed decrease in CXCR5 expression in SS results from relocation of CXCR5-
highly-positive B cells from blood stream to the salivary glands. 
T follicular regulatory (TFR) cells also express CXCR5, and the frequency of circulating 
TFR was suggested a biomarker of degree of tissue inflammation and autoantibody 
production in SS and rheumatoid arthritis. We could confirm the elevated frequencies of 
TFR in the blood of SS patients, and show that most of them have a naïve phenotype. 
B cells are producers of the SS hallmark autoantibodies against Ro and La, that have been 
used for diagnostic purposes for decades. In this thesis we investigated the anti-
inflammatory and anti-proliferative properties of TRIM21/Ro52, one of the targets of anti-
Ro. We studied the role of Trim21 in the homeostasis of mouse B cells, and the relevance 
of TRIM21 as a prognostic marker in diffuse large B-cell lymphoma. In Trim21 knockout 
mice, B cells had a higher rate of proliferation, follicular B cells were expanded and higher 
levels of both IgM and IgG were generated after immunization with both thymus dependent 
and independent antigens engaging the B cell receptor. In accordance with these data, 
maintained TRIM21 expression was associated with a better prognosis in diffuse large B-
cell lymphoma, independently of subtype and underlying autoimmune disease. 
Another severe comorbidity in SS and SLE affects foetuses and newborns of the patients. 
Maternal Ro and La autoantibodies are transferred to the developing foetus, and in 2% 
cases this leads to a congenital heart block (CHB), a part of neonatal lupus. Here, we 
studied signs of inflammation in the cord blood of neonates exposed to maternal anti-
Ro/La. We observed an elevation of serum type I interferon (IFN) levels and an IFN-gene 
signature in autoantibody-exposed neonates. Besides, neonatal PBMC proved to be capable 
to produce IFN in vitro, suggesting a possible foetal origin of the cytokine. Further, we 
show increased frequencies of circulating natural killer cells, and presence of type II IFN in 
the sera of some of these newborns. These novel findings contribute to the understanding of 
the mechanisms behind CHB. 
In summary, we connect genetic variants of the CXCR5 gene locus to expression patterns 
and cell compartmentalization in SS, demonstrate a role of the autoantigen TRIM21 in B 
cell homeostasis and function and present evidence for innate immune activation in Ro and 
La autoantibody-exposed newborns. 
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1 INTRODUCTION 
 
1.1 Systemic autoimmune diseases: Sjögren´s syndrome and systemic lupus 
erythematosus  
Primary Sjögren’s syndrome (SS) and systemic lupus erythematosus (SLE) are systemic 
autoimmune diseases with an incidence of 3-10 cases per 100,000 person-years in Sweden 
each.1,2 SLE is characterized by a heterogeneous clinical picture, and may have a severe 
course, primarily due to kidney, heart and nervous system damage. SS, which has a 
substantial clinical, genetic and immunological overlap with SLE, although often with a 
milder disease course, primarily affects exocrine organs, leading to oral and/or ocular dryness 
(sicca symptoms). Major extraglandular manifestations (EGM) include fatigue, myalgia, 
arthralgia and hematological involvement, and can have a severe impact on patients’ lives.3 
SS is mostly not a life-threatening disease, however the risk of developing non-Hodgkin B-
cell lymphoma is up to 16 times higher than in the general population.4-6 In SLE, this risk is 
3–5 times higher than that of the general population.5,7 
The main diagnostic hallmarks of SS are xeropthalmia and xerostomia, confirmed by 
histological and functional tests, as well as autoantibody positivity (details are discussed in 
the following section).8 In SLE, patients display autoantibody positivity, decreased levels of 
complement proteins C3c and/or C4 and involvement of one or two target organs.9,10 The 
diversity of manifestations motivated the European League Against Rheumatism (EULAR) 
and the American College of Rheumatology (ACR) to develop classification criteria for SS 
and SLE, in order to stratify patients into more homogenous groups. One important 
advantage of the updated criteria is refined patient grouping for research purposes. The latest 
versions of the criteria with special focus on early SS and SLE were established in 2016 – 
2017.9,11,12 
In addition to classifications, disease activity indexes (ESSDAI, SLEDAI and other) and 
patient reported indexes (ESSPRI, SLAQ and other) were designed to assess disease severity 
and activity as well as facilitate personalized management strategies.13-15 
 
1.2 Autoantibodies  
The concept of autoimmune diseases infers the involvement of adaptive immunity, and in 
systemic autoimmune diseases a central role is traditionally given to autoantibodies, produced 
by B cells. Interestingly, disease-specific autoantibodies can sometimes be detected years 
before the appearance of the first clinical symptoms of the disease.16 One of the first 
serological tests developed was for the detection of anti-nuclear antibodies (ANA).8 It is 
commonly performed using a model cell line, HEp2, and patient autoantibodies are detected 
with immunofluorescence.17 A positive result does not identify any particular antibody 
specificity, but the pattern of immunofluorescence often indicates the presence of several 
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types of autoantibodies. ANA titer of ≥1:320 is suggestive of SS,3 and ≥1:80 – of SLE.12 The 
umbrella term of ANA typically includes: anti-dsDNA, anti-Sm, anti-RNP, anti-DFS70, sp-
100, PML, Ro/SSA (anti-Ro52 and anti-Ro60), La/SSB and more. Anti-dsDNA antibodies 
are included in the classification criteria of SLE12 (present in 70 – 80% of patients),18,19 and 
Ro/SSA antibodies in the criteria for SS (present in 40 – 75% of patients).8 La/SSB were 
previously a part of the criteria for SS, but were omitted in the latest version after statistical 
modelling demonstrating they did not add to the precision of the criteria.20 
Ro/SSA, La/SSB and the possible role of one of their targets, TRIM21/Ro52, in the 
pathogenesis of SS and SLE and comorbidities are discussed further in this thesis. 
 
1.3 Interferon in Sjögren’s syndrome and systemic lupus erythematosus  
In SS and SLE and other systemic autoimmune conditions (such as systemic sclerosis and 
idiopathic inflammatory myositis) the interferon system is often continuously activated, and 
these diseases are frequently referred to as interferon-driven.21 Indeed, accumulating evidence 
suggests that the autoantibodies to ribonucleoproteins, paired with a decreased ability of 
clearing cellular debris, triggers IFNα production in pDC and other cells.22 The elevation of 
levels of type I IFN, a cytokine which has its primary function in protection against microbes, 
has broad direct and indirect consequences for the immune cell homeostasis. Below, I have 
chosen to highlight the effects most relevant for the current studies. 
Altered expression of multiple cell-surface molecules 
Type I IFN regulates function, survival and location of immune cells, among other ways, by 
modifying cell surface molecule expression. The upregulated molecules include activation 
markers CD69, CD86, CD25, PD-1, MHC class I molecules, chemokines CXCR3, CXCR4, 
CXCR5 and many other.23,24 In contrast, type I IFN downregulates membrane-bound IgM.25 
The data describing the role on the expression of CD95 (FAS) are controversial. On one 
hand, it was shown that type I IFN downregulates CD95,25 however immunoglobulin class 
switched memory B cells in SLE are CD95-positive.26 MHC class II receptors in B cells do 
not seem to be regulated by type I IFN alone, but are upregulated upon synchronic BcR 
signalling.25 In monocytes and DCs on the other hand, IFN is sufficient to upregulate HLA-
DR.27,28 
Effects on B cell fate decisions 
In absence of other stimuli, the only effect of type I IFN on resting B cells is prolonged 
survival.25 Except for downregulation of CD95, IFN-dependent B cell survival is mediated 
through upregulation of the anti-apoptotic molecules BCL-2 and BCL-XL.23,25 Enhanced B 
cell proliferation was observed upon simultaneous stimulation with type I IFN and anti-IgM, 
which was further increased upon addition of CD40 antibody or IL-4.25 Finally, the 
upregulation of transcription factors BLIMP and XBP, induced by type I IFN, drives B cells 
towards differentiation into plasma cells (PC).23 Taken together, these effects result in 
intensified production of antibodies, including those with autoreactive potential.29 
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Intracellular signalling component expenditure 
Type I IFN signalling is negatively regulated at both transcriptional and post-transcriptional 
levels. One of the main transcription repressors of interferon-stimulated response element 
(ISRE)-containing genes is IRF2.30 Multiple IFN-induced proteins specifically target 
cytosolic nucleic acid sensors RIG-1 and MDA5 and signalling component downstream them 
(MAVS, STING).28 Also, IFNAR subunits themselves can be downregulated.31 A prominent 
negative regulation mechanism at the protein level is ubiquitination. There is a variety of 
IFN-induced E3 ubiquitin ligases that target products of interferon-stimulated genes (ISG): 
A20, an interesting and potent inhibitor of NFκB and TNF signalling, and a tumour 
suppressor,32,33 RNF125, IFI35,28 as well as multiple TRIM family members.34 Of these, 
TRIM21 has been of our particular interest, as it was first described as an autoantigen in SS 
and SLE.35,36 These signalling repressors are themselves ISG, and are therefore expressed, at 
least partially, in a dose-dependent manner. However, the chronic nature of the signalling 
pathway activation in SS and SLE might have unexpected consequences, e.g., insufficiency 
of negative regulators. Additionally, their broad specificities and targets outside IFN 
pathways makes it difficult to predict the long-term effects of chronic exposure to type I IFN. 
Besides rapid upregulation during infection, low concentrations of type I IFN are constantly 
present in the primary and secondary lymphoid organs.25,28,30 This basal expression is 
controlled by the transcription factors IRF3 and IRF7, which allow rapid IFN self-
amplification when infection occurs.30 Lymphocytes deprived of basal IFNAR pre-
stimulation require more time for activation.24,30 Interestingly, in bone marrow-derived 
myeloid cells, low IFNβ expression is controlled by M-CSF and AP-1 transcription factors, 
and has an antiproliferative effect.28,37 
Type II IFN 
The role of IFN in SS and SLE is less well established. Detection of IFN in serum requires 
high sensitivity assays, thus the presence of circulating type II IFN in SS and SLE has 
become apparent only recently. Up to 30% of patients have detectable levels of this potent 
cytokine in blood, however the significance of this finding is not entirely understood.38,39 
 
1.4 TRIM21/Ro52 
Tripartite motif-containing protein 21 (TRIM21) or Ro52 is a RING-dependent E3 ubiquitin 
ligase,40,41 and it is best known as a negative regulator of TLR signalling.42,43 It is 
predominantly expressed in cells of hematopoietic lineages. Besides the first identified 
ubiquitination targets IRF3, IRF7, IRF5 and IRF8 downstream of TLR,43-47 TRIM21 was 
suggested to interact with BCL-2,48 TRAF6,49 IKKb,50 FLASH, DAXX,51 DDX41,52 C-FLIP 
and C/EBPα.53 In human, the TRIM21 gene maps to 11p15.4 and contains seven exons; the 
full-length transcript yields 475 aa product. In mouse, the Trim21 gene is located at 7E3, 
contains eight exons (six are coding), and encodes a protein of 462 aa. Polymorphisms in the 
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TRIM21 gene have been associated with SS and SLE,54,55 although GWAS projects have not 
been successful in replicating the association.56-58 
TRIM21 was discovered as an autoantigen, and is targeted by autoantibodies in 50 – 70% of 
patients with SS,59 in up to 98% cases of autoimmune hepatitis,60 35 – 40% of SLE cases,61 
and in 10 – 20% of RA, 36% of polymyositis and 20% systemic sclerosis patients.62 
Autoantibodies towards Ro52/TRIM21 and an unrelated protein Ro60 are traditionally 
denoted Ro/SSA autoantibodies. The main epitope of Ro52 is situated within the central 
coiled-coil region of the protein, but it is anti-Ro52 antibodies binding the RING domain of 
TRIM21 that can block its ubiquitinating activity in vitro,44 however, whether the 
autoantibodies inhibit the intracellular enzyme in vivo remains unclear.  
Two Trim21 knock out mouse models were generated independently in 2009.44,63 Both 
research teams used a GFP reporter, but their vectors targeted different exons of Trim21. The 
construct designed by Yoshimi et al. removed the expression of virtually the whole Trim21 
mRNA, while Espinosa et al. used a vector which theoretically enabled the expression of a 
truncated protein. While in the former model, only a mild phenotype was observed,63 the 
latter mice developed an autoimmune-like condition provoked by metallic ear-tags. This 
autoimmune phenotype included severe dermatitis, nephritis, hypogammaglobinaemia 
(mainly IgG1 and IgG2) and ANA production as well as splenomegaly and 
lymphadenopathy.44 This phenotype is thought to be mediated, at least partially, by 
IL23/IL17,44 however, Th17 cells, differentiated from ex vivo naïve Trim21-/- CD4 cells, 
displayed a gene signature of non-pathogenic subset of Th17.64 The phenotypical differences 
between the two Trim21-/- mouse models were explained by the compensational upregulation 
of other proteins of TRIM family in mice generated by Yoshimi, but not in those from 
Espinosa et al.65,66 
 
1.5 Immune cell aberrations in Sjögren’s syndrome and systemic lupus erythematosus 
1.5.1 B cells 
The role of B cells in SS and SLE is illustrated by multiple findings related to humoral 
immunity: hypergammaglobulinemia and elevated levels of immune complexes and 
autoantibodies, B-cell infiltration of the inflamed tissues and increased risk of B-cell 
lymphomas.67,68 Taken together with the abundance of B cell activating factor (BAFF) and 
IL-21, these phenomena underline the importance of examining B cell subsets in SS and SLE. 
BAFF and IL-17A overproduction 
BAFF is directly upregulated by IFNα,29,69 and, in turn, promotes Th17 production, by 
several cell types. This cytokine trio creates a positive feedback between T and B cells within 
the germinal centers (GC) and also recruits monocytes and mDC.21,29 BAFF is one of the 
master regulators of B cell differentiation. It is critical for the survival of immature B cells at 
the T2 stage,70,71 as well as mature naïve and memory cells including autoreactive.71,72 This 
makes BAFF availability a risk factor for a tolerance breakdown,73 and, indeed, BAFF knock-
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in transgenic mice develop a lupus like disease.74 BAFF acts mechanistically through the 
NFκB pathway.75 Other notable effects of the type I IFN–BAFF–IL17 axis are the promotion 
of differentiation of activated T cells towards Th1721 and IL-21-producing TFH,76 and the 
reinforcement of the monocyte differentiation into mDC.29 
Naïve, marginal zone and class-switched memory B cells 
In both SS and SLE findings typical in the circulating B cell population are a higher 
frequency of naïve B cells and a lower frequency of both CD27-positive compartments, class-
switched memory and marginal zone (MZ) B cells.26,67,68,76 For other B cell subsets (plasma 
cells, plasma blasts, double negative, transitional B cells) aberrations vary between the 
patients26,68 and become apparent exclusively in clinically pronounced cases, e.g. 
accompanied by EGM.76 Nevertheless, the decrease in the percentage of circulating MZ B 
cells has repeatedly been observed in both SLE and SS.26,67,68,76 MZ subpopulation is also 
called unswitched memory, natural effectors or IgM memory cells. These cells are long-lived, 
have a history of antigen encounter and can expand and undergo BcR editing without 
interacting with T cells.77 Microarray data from circulating MZ B cells68 and upregulation of 
their surface molecules such as CD95 (FAS), CD80 and CD8626 suggest that MZB are 
activated in SS and SLE.68,78 
Interestingly, MZ B cells in SS and SLE overexpress the chemokine receptors CXCR3, 
CXCR4 and CXCR5, and were shown to home to the sites of inflammation, e.g. salivary 
glands (SG).26,76 This MZ subpopulation displayed signs of antigen encounter (proliferation 
and somatic hypermutation, SHM) and comprised up to 50% of autoreactive cells in blood in 
SS patients.67 Moreover, a part of MZ B cells from healthy donors stimulated in vitro with 
CpG, temporarily expressed activation-induced deaminase (AID), underwent class-switching 
(as well as SHM)5,71 and rapidly differentiated into antibody-producing cells. Whether this 
occurs also in vivo is unclear, as, for instance, it is difficult to distinguish MZ cell that 
travelled to the SG and class-switched in situ from classical CD27+IgM-IgD- memory cell. 
The accumulation of the latter in ectopic lymphoid tissues was, indeed, observed in multiple 
studies, which could explain the decrease in the circulating CD27+ memory B cells.67,79 
Another possible contributor is enhanced differentiation of memory B cells and plasmablasts 
into plasma cells, accompanied by shedding of the CD27 receptor. Indeed, elevated levels of 
soluble CD27 were observed in both SS80 and SLE81 and associated with higher IgG levels 
and disease activity. 
Plasmablasts, plasma cells, transitional and double-negative B cells 
Other B cell subpopulations affected in SS and SLE include transitional, double-negative 
(DN, CD19+CD27-IgD-), plasmablasts and plasma cells. In SLE, the proportion of circulating 
DN cells is increased.68 In contrast, in SS the DN percentage is decreased, but only in severe 
cases. The same was true for plasmablast and plasma cell relative counts: they were increased 
in a subset of SLE patients26,76 and, on the contrary, decreased in SS, the latter being 
considered a consequence of CXCR3 and CXCR4 overexpression.76 After immune triggering 
by vaccination, the amount of circulating plasmablasts was increased also in SS compared to 
healthy donors.82 Elevation of antibody producing B cell counts might result from enhanced 
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cytokine impact on differentiation or survival of cells, including autoreactive.76 An increased 
proportion of circulating transitional CD24highCD38high cells observed in SLE might arise 
from similar mechanisms: dysregulation of chemokine receptors or/and diminished negative 
selection.76 Interestingly, anti-Ro52 antibodies isolated from a patent with SS displayed low 
levels of somatic hypermutation, suggesting an origin from immature (naïve) B cells avoiding 
tolerance.83 
Age-associated B cells  
In 2011, two groups have described a novel B cell population, designated age-associated B 
cells (ABC).84,85 As the name suggests, those cells accumulate with age in both mice and 
humans, and have been identified in spleen, blood and bone marrow.86 Differentiation of 
ABC depends on transcription factor T-bet,85 and they are defined as CD11c+CD21low/-
CD5highCD23low/-CD95high in healthy human and naïve mouse with slight variation in 
phenotype between the studies.86,87 Interestingly, for the effective activation, ABC require 
TLR7/9 ligands and IFN in addition to BcR ligation.86 ABC function as producers of IFN, 
IL-10 and TNF and preferentially IgG2. To date, ABC have been investigated in SS, SLE, 
MS, infections and common variable immune deficiency.87,88 
1.5.2 T cells 
Decreased numbers of circulating T helper (Th) cells have been described in both SS and 
SLE patients.89-91 Further, the balance between Th17 and Treg seems to be shifted towards the 
former.92,93 Th17 cells appear to be important contributors to the ectopic lymphoid tissue 
formation at early stages in SS, as they are attracted by CXCL9 and CXCL10 secreted by 
activated SG resident cells and amplify and sustain the inflammatory signalling by producing 
IL-17 and IL-22, that activate B cells and support SG epitheliocytes.93 Interestingly, a subset 
of Th17 cells expressing CXCR5 has been identified in juvenile dermatomyositis,94 SS95 and 
RA.96  
An important finding in the T cell compartment in systemic autoimmunity is also the elevated 
frequency of circulating T follicular helper (TFH) cells, expressing CXCR5, and high levels of 
PD-1 and ICOS in a subset of SS and SLE patients with severe clinical course.76 Also, higher 
levels of IL-21, a cytokine produced by TFH, and higher ANA titers were observed in these 
patients.76,97 Notably, IL-21 is a potent B cell differentiation factor and may also sustain the B 
cell activity in the patients.94,98 
T follicular regulatory (TFR) cells, another component of CXCR5-positive T cell pool, are 
suppressors of GC B cell activity99-101 and, unlike conventional Treg, require expression of 
BCL-6.102 In autoimmune conditions their abundance in GC negatively correlates with 
autoantibody production,103 however their circulating counterpart seems to have restricted 
immune suppressive properties and their prevalence is rather an indirect indication of 
ongoing inflammation.104 
1.5.4 Natural killer cells 
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NK cells are a type of innate lymphoid cells (ILC1) bearing both cytotoxic and cytokine 
producing functions. A variety of activating and inhibitory NK cell receptors were identified 
that convey self-non-self discrimination or presence of cytokines. Classically, NK cells with 
predominantly cytotoxic functions are defined as CD16+CD56low, and cytokine producing 
NK cells are CD16low/-CD56+.105 A third type, CD16-CD56high decidual NK cells, with 
exclusively cytokine production properties, are vital for the first trimester of pregnancy, when 
they orchestrate vascularization and placentation by VEGF, CXCL10 and CXCL12 
secretion.106 Both circulating and tissue resident NK cells, e.g. in SG and skin, can produce 
IFN, IL-10 and TNF, exhibit direct or (auto)antibody mediated cytotoxicity and possess 
plasticity, and thus may have a dual role in autoimmunity.107 
In SS patients, Davies et al. demonstrated deviations in absolute counts of circulating NK 
subsets in different clusters of patients, which were also partially treatment-dependent.91 
Similarly, Seror et al. observed that a subgroup of SS patients responding to the anti-BAFF 
monoclonal Belimumab had lower NK cell SG infiltration.108 The interpretation of these 
findings seems controversial in terms of the NK cell role (immunosuppressive vs 
stimulatory), compartmentalization, cause vs consequence, and treatment vs disease 
subtype/severity.  
1.5.3 Plasmacytoid dendritic cells  
pDCs are the main type I IFN producing cells. Upon stimulation by nucleic acids or nucleic 
acid-containing immune complexes cytosolic RIG-I–like receptors (RLRs) or the endosomal 
TLR7 and TLR9 receptors are activated and large levels of IFNs are produced.109 pDCs are 
also effective at antigen presentation and chemokine (CCL3, CCL4, CXCL9, CXCL10) and 
cytokine (IL-6, IL-12) production, thus potentially contributing to autoimmunity.110 pDCs 
were not a focus of this thesis, but are discussed in the results section in relation to our data. 
Direct consequences of type I IFN production were extensively studied, however pDCs were 
recently found to be involved in novel pathological pathways in autoimmunity. Zhao et al. 
suggested a model of ectopic GS formation, where pDC-derived IFN induced CXCL13 
production by MФs, which in turn attracted TFH and CXCR5-positive B cells.111 Co-culturing 
B cells with pDC in presence of immune complexes turned out to directly force class-
switched memory B cells to acquire DN phenotype, shedding light on the origin of skewed B 
cells subset composition in SLE.112 
 
1.6 Comorbidities in Sjögren’s syndrome 
An increased risk of B-cell lymphoma has been well documented in Sjögren’s syndrome,4-7 
and multiple large epidemiological studies summarized by Pego-Reigosa et al. also indicated 
higher risks of fibromyalgia and infections (primarily candidiasis and tuberculosis) and 
slightly higher risk of dyslipidaemia, cardiovascular disease and thyroid cancer in SS 
compared to the general population.113 There is also a risk for neonatal lupus in the foetus of 
pregnant women with SS. In my thesis work, I have studied two of the comorbidities of SS; 
non-Hodgkin lymphoma (NHL) and neonatal lupus erythematosus. 
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1.6.1 B-cell lymphomas 
The most frequent autoimmunity-associated lymphoma types are mucosa-associated 
lymphoid tissue  (MALT) lymphoma and diffuse large B-cell lymphoma (DLBCL). 
DLBCL is the most frequent NHL (30 – 40% of all cases) with an aggressive course, and 
comprising two major molecular subtypes described in 2000 by Alizadeh and colleagues; 
germinal center B cell-like (GCB) and activated B cell-like (ABC).114-116 The other DLBCL 
subtypes, e.g. primary mediastinal B-cell lymphoma, are very rare, and will not be discussed 
here. Multiple studies of SHM and gene expression signatures indicate that DLBCL cells are 
derived from mature GC B cells (GCB subtype) or post-germinal B cells (ABC subtype).5,115 
GCB DLBCL cells resemble normal GC B cells, as they hold the immunohistochemistry 
hallmarks of ongoing SHM, express CD10, CD38 and transcription factor BCL-6, which 
inhibits their differentiation and facilitates proliferation. The most specific markers for ABC 
DLBCL cells is expression of c-MYC, IRF4 and mutations in FLIP and MYD88, which 
reflect the constantly “activated status” of these cells, and ensures their reduced 
responsiveness to apoptotic and differentiation stimuli.5,115,117-119 The overexpression of 
hallmark molecules (BCL-6, IRF4, c-MYC) in DLBCL often results from translocations, 
especially to the Ig locus, but can also arise from in situ mutations (MYD88, FLIP).5,115 
Attempts are currently being made to identify genetic biomarkers of tumour subtype using 
genomics and transcriptomics: next-generation sequencing,120 whole exome sequencing, 
nanostring,121 and reverse transcriptase multiplex ligation-dependent probe amplification,122 
which can be used for paraffin-embedded biopsies. The prognosis is significantly better in 
GCB DLBCL compared to the ABC group.115,117,118 
Mucosal Associated Lymphoid Tissue (MALT) lymphomas are a subset of MZ lymphomas, 
and are the most common lymphoma subtype in SS.114 The MZL group contains both 
somatically mutated and non-mutated subtypes, and can originate from post-GC B cells or, 
intriguing, from outside GC and even lymphoid tissues in a T-cell independent fashion 
(extranodal lymphomas)5,123 MZ lymphomas, including MALT, are thought to derive from 
MZ B cells. MALT lymphomas display fewer translocations than DLBCL, but more point 
mutations. However, there are some typical translocations in extranodal MALT, such as 
API2-MALT1 and BCL-10 and MALT1 translocations to the Ig locus, which result in 
constitutive NFκB signalling through TRAF2 and TRAF6.5 The point mutations seem to 
result from the SHM, and include c-MYC, BCL6, CDK2A/B, PAX5, A20, and FAS.5,123 
In MALT lymphomas, chronic inflammation and infections play important roles in 
pathogenesis. Anti-apoptotic signalling through BcR, activation via PRR and co-stimulatory 
molecules, and the cytokine environment all interact to maintain cellular survival and high 
proliferation rates. Gastric MALT lymphoma is driven by Helicobacter pylori and is regarded 
as a classic example of infection-related cancer. MZL of other locations are also associated 
with infections, such as ocular, cutaneous, splenic and small intestine MZLs.5,123 The 
common mechanism behind the lymphomagenesis is, again, NFκB signalling and during the 
first stage, it is BcR or TLR-dependent (and often T cell-independent).123 In the context of the 
salivary glands, this first stage is called lymphoepithelial sialadenitis (LESA), and it can be 
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regarded as a transition step to lymphoma, with the hyperproduction of several clones of 
antibodies, including autoreactive ones.5,124 
Phenotypically, MALT lymphoma cells are BCL-6, CD5 and CD10-negative, but bear 
several MZ B cell markers, such as CD20, CD27, CD21/35, IgM and IgD. However, their 
phenotype differs slightly between the studies.5,124 
1.6.2 Lymphomas in autoimmunity 
Multiple factors of inflammation might predispose to lymphoma development, and type I IFN 
exposure is potentially one.125,126 At the same time, type I IFNs are considered to have direct 
(anti-proliferative, pro-apoptotic) and indirect (activation of NK cells, cytotoxic T cells and 
pDC to present oncoantigens) tumour-suppressor effects. Moreover, IFNα is an approved 
therapeutic agent in melanoma, breast cancer, hairy cell leukemia and CML, although with 
limited effect and use, partially due to side-effects.31 Since MALT lymphomas and some 
DLBCL develop in an environment of the elevated type I IFNs (viral infections, SS, SLE, 
RA), one could speculate that the IFN tumour-suppressor mechanisms are disrupted in these 
conditions.31,127 Moreover, the unresponsiveness to the IFN, logically, should be a 
prerequisite to a successful lymphoma development. On the other hand, type I IFN induces a 
variety of effects, that potentially promote oncogenesis (described in more detail in Type I 
interferon in the SS and SLE section). Ngo and colleagues observed the signature of IL-6, IL-
10 and IFNβ signalling in ABC DLBCL cell lines with hyperactive MYD88.33 IFNβ was also 
present in the supernatant of the human B-cell lymphoma OCI-Ly3 cell line, which, 
according to authors, could be an autocrine mechanism, promoting lymphoma survival. 
The NFκB pathway is the major regulator of B cell activation and differentiation, with 
extremely broad outcomes, including survival, proliferation, cytokine production, SHM and 
CSR.128 NFκB signalling dysregulation has been reported as one of the key pathogenetic 
mechanisms of lymphomagenesis of MALT lymphoma in SS and DLBCL in SLE and 
RA.5,123-125,129,130 NFκB activation occurs through stimulation of the BcR complex, as well as 
through co-stimulatory molecules (mainly of TNF receptor superfamily) and TLR.50,129,131 
Except for NFκB and type I IFN, PI3K pathway is also often active in the chronic BcR 
stimulation,129 as well as upon the CD40 ligation,132 which provides additional survival 
signalling. 
A well-studied link between autoimmunity and oncogenesis is provided by the NFκB 
inhibitor A20 (TNFAIP3). A20 is upregulated upon TLR and TNF stimulation to create a 
negative feedback loop for NFκB. Single nucleotide polymorphisms (SNP) and mutations in 
the A20 locus were found in 60% of SS-associated lymphomas.123 Other shared susceptibility 
loci between autoimmune diseases and lymphomas include HLA133 and, intriguingly, 
CXCR5.41,134 
1.6.3 TRIM21 and cancer 
Overexpression of Trim21 in the lymphoma B cell line A20 leads to activation-induced 
apoptosis upon stimulation through CD40,41 indicating the involvement of NFκB signalling. 
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TRIM21 was shown to negatively regulate NFκB signalling through interactions with 
TRAF649 and IKKb,50 although it might have targets at other levels that are not yet 
investigated, e.g. TRAF3 and MAP kinases. Another tumour suppression mechanism of 
TRIM21 may be ubiquitination of its reported target BCL-2,48 a central anti-apoptotic 
molecule, upregulated in many cases of lymphoma. These direct and indirect observations of 
a possible role for TRIM21 in cancer has led investigators to explore expression of TRIM21 
in different forms of malignancies. To date, maintained TRIM21 expression turned out to be 
a beneficial prognostic factor in hepatocellular carcinoma135 and breast cancer,136 but, 
opposingly, predicted for shorter survival in pancreatic cancer and showed no prognostic 
value in colorectal cancer.137 
1.6.4 Congenital heart block 
The presence of maternal Ro/SSA (anti-Ro52 and anti-Ro60) and La/SSB (anti-La) 
autoantibodies during pregnancy is associated with a risk of neonatal lupus erythematosus 
(NLE) in the child, which includes congenital heart block (CHB), skin manifestations, liver 
and hematological involvement. IgG is known to be transported across the placenta during 
pregnancy, and Ro/SSA and La/SSB autoantibodies have been shown to be transferred to the 
foetus. The autoantibodies are found in > 95% of the cases of in utero CHB138,139, a rare 
condition that develops in the foetus at gestation week 18 – 24 and refers to a complete third 
degree atrioventricular block (AVB III), but is sometimes also used to indicate lower degrees 
of AV block and/or other cardiac manifestations such as endocardial fibroelastosis. It 
manifests as markedly decreased heart rate, usually less than 70 bpm, versus expected 120 – 
160 bpm.140 The reported mortality is variable, but generally high, 4 – 19%,140-144, and is 
usually related to a more generalized cardiac involvement such as dilated cardiomyopathy 
and endocardial fibroelastosis. Fluorinated steroids administrated to the mothers, cross the 
placenta and have shown to inhibit the progression of second-degree AV block. Recent 
publications report that the anti-malaria drug Hydroxychloroquine (HCQ) might reduce the 
risk of CHB.145-147 
The studies discussed here, address specifically autoantibody-associated CHB. Anti-Ro52 
IgG purified from maternal sera, as well as Ro52 monoclonal antibodies, induced CHB in 
mouse and rat pups, although the antibodies targeting the human protein did not bind Ro52 in 
rodents.139,148 Whether maternal autoantibodies bind their conventional targets in human fetal 
heart remains one of the unsolved questions in CHB. One possibility is a so-called apoptosis-
inflammation hypothesis, which includes translocation of Ro/La to the extracellular space as 
a part of physiological apoptosis in fetal conduction cells, followed by antibody binding and 
inflammation.149 Another theory is cross-reactivity of maternal autoantibodies with non-
Ro/La related epitope(s) expressed in the fetal heart. Several alternative autoantigens, as well 
as autoantibodies,138,150 have been suggested, including calcium channels,151 calreticulin,150 a 
serotonin receptor 5-HT4152,153 and several more. Of interest, autoantibodies of M class to 
calreticulin were detected in anti-Ro/La exposed neonates, and especially in CHB (this study 
did not include HD),154 and anti-Ro60 IgM was found in both healthy and, at increased levels, 
in autoantibody-exposed subjects.155 
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The association of CHB with anti-Ro/La antibodies is well established, but a recurrence rate 
of only 12 – 20% in following pregnancies despite persisting maternal autoantibodies,156 
suggests that additional factors are required for disease development. These may be 
immunological, pregnancy-related, genetic or environmental.157,158 
1.6.5 Neonatal immunity 
Except for anti-Ro/SSA and anti-La/SSB-positivity, not many immunological parameters are 
known to predispose for CHB. Here, I’ll focus on cellular and molecular aspects of this 
condition. 
The physiological umbilical cord cell composition and status display striking differences 
compared to adult peripheral blood. The major cell differences include presence of myeloid, 
lymphoid and erythroid precursors and stem cells as well as the well-established neutrophilia 
and relative lymphopenia, that reverse at the fifth day of life.159 In the B cell compartment, 
the cells transitional and naïve B cells are of the highest frequencies throughout ontogenesis, 
while switched memory and MZ B cells are of the lowest frequencies.160,161 The same logic 
applies to the T cell compartment: a high prevalence of naïve T cells and decreased numbers 
of memory cells of both helper and cytotoxic subsets. Low frequencies of Treg, and absence of 
CXCR5-expressing TFH are common findings.162 Both absolute and relative numbers of NK 
cells are increased in the cord blood. Immunological profiling of cord blood, including the 
humoral (immunoglobulins, cytokines) and cellular (activation markers, MHC expression) is 
comprehensively reviewed in Basha, Surendran and Pichichero, 2014.163 
1.6.6 Pregnancy and autoimmunity 
Pregnancy is a complex process, involving a variety of immune and non-immune factors and 
interactions that drastically change over time. Several cell types are involved during a 
successful pregnancy, the process of implantation requires a low degree of inflammation 
while excessive inflammation might cause implantation failure or miscarriage. The major 
findings in blood cell composition in late pregnancy were known before the flow cytometry 
era and include granulocytois, monocytosis and lymphopenia.164,165 The expansion of 
granulocyte and monocyte fractions conforms to the high levels of both G-CSF and M-
CSF.166 Intriguingly, besides high counts, monocytes display an activated phenotype.165 
Absolute and relative B cell lymphopenia is also a well-established phenomenon associated 
with gradual oestradiol increase throughout pregnancy.167 Lima and colleagues reported that 
this decrease in B cell counts mainly resulted from a decrease in transitional, MZ, DN B cells 
and plasmablast subpopulations, while naïve B cells counts were intact, and Breg counts were 
increased.168 Muzzio et al. confirmed the suppression of B cell lymphopoiesis in mice, 
resulting from reduced BM precursors and decreased BAFF levels.167 
Several studies, but not all, indicated a general T cell lymphopenia in humans and rats during 
pregnancy.166,169 In the second trimester, a decrease in Treg percentages has been observed, 
while activated CD25high T helper frequencies, on the contrary, were increased.170 Late T cell 
patterns of PBMC in pregnancy also include alterations in the Th1/Th2 ratio.165,166 Both 
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cytotoxic and cytokine producing activities of NK cells seem to be gradually suppressed 
throughout pregnancy, as well as frequencies of circulating CD56dim NK cells, while 
CD56bright NK relative cell counts remain stable.166 
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2 AIMS 
SS and SLE are frequent and severe autoimmune diseases of great societal impact. A genetic 
basis for SS has been suggested, including polymorphisms in the CXCR5 gene locus, but the 
association remains functionally unexplained.  
Trim21/Ro52 knock out mice display signs of systemic inflammation and splenomegaly, 
while Trim21 overexpression restricted the growth of a mouse B cell line. Further, 
maintained TRIM21 expression has been proposed as a good prognostic marker in several 
types of cancer. Taken together, these observations point to a potential role for TRIM21 in B 
cell homeostasis.  
Finally, Ro/SSA and La/SSB autoantibodies are associated with a passive autoimmune 
condition, neonatal lupus erythematosus (including congenital heart block), that may affect 
the foetus of women carrying these autoantibodies. However, the mechanisms driving the 
inflammation in the exposed foetus are unclear. 
 
The aims of the current thesis were therefore to: 
- link genetic variants of the CXCR5 gene locus to expression patterns and cell 
compartmentalization in SS; 
- investigate the role of the autoantigen TRIM21/Ro52 in B cell homeostasis and function; 
- characterize immune activation in newborns of Ro/SSA and La/SSB autoantibody-positive 
mothers. 
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3 RESULTS AND DISCUSSION 
 
3.1 Genetic and cellular features of CXCR5 in Sjögren’s syndrome 
Genetic susceptibility contributes to the development of autoimmune and rheumatic diseases. 
Among other genetic variants, polymorphisms in a locus on chromosome 11q23.3 were 
identified as associated with Sjögren’s syndrome in a GWAS published by Lessard and 
colleagues in 2013.58 The peak of the genetic association signal includes two genes; DDX6 
and CXCR5. To understand if the expression of either gene was dependent on cis-genotypes, 
we first ran an eQTL analysis in an independent cohort of healthy donors (HD) described by 
Fairfax et al.171 Since the specific SNPs identified by Lessard et al. had not been typed by 
Fairfax, a proxy SNP (rs4938573, LD r2 > 0.8) was used. The analysis demonstrated that the 
disease risk allele (T) was associated with a significantly lower expression of CXCR5 in 
CD19+ B cells. In Papers I and II, we aimed to connect this genetically based observation 
with the pathological process in SS. 
3.1.1 eQTL effect in CXCR5 gene locus might be explained by B cell redistribution 
(Paper I) 
CXCR5 is a chemokine receptor expressed on B and T cells required for their homing to 
follicles in secondary lymphoid organs. We therefore assessed CXCR5 expression profiles on 
B and T cell populations in a cohort of untreated SS patients. Within the B-cell compartment, 
we first confirmed previous findings in SS patients, such as lower frequencies of marginal 
zone (MZ) B cells, accompanied by tendencies towards higher naïve and lower memory B 
cell prevalence compared to HD. Some of the patients had higher CD19+ B cell frequencies 
than HD. As described previously, most circulating B cells expressed CXCR5.172 
However, in the SS patients, the frequencies of CXCR5-positive cells among total B cells 
were reduced, resulting from lower frequencies of CXCR5 positive memory, MZ and CD27–
IgD– double‐negative (DN) subsets. This observation complemented our eQTL analysis 
results. Moreover, the cell surface expression levels of CXCR5 followed a similar pattern, 
with significantly lower median fluorescence intensity (MedFI) in memory and DN B cells. 
Interestingly, naïve B cell proportions in SS patients tended to be increased, while the 
difference in their surface CXCR5 expression between HD and SS patients appeared 
minimal. CXCR5 expression is known to gradually increase throughout B cell differentiation, 
and reaches a plateau at the follicular/naive B cell stage.173  
T cell homing to GC appears to differ from that of B cells: T cells require antigen encounter, 
downregulation of CCR7, and transitional upregulation of CXCR5, which is re-enforced in 
the GC.174,175 Indeed, in HD, circulating CXCR5-positive T cells expressed 2 – 3 times lower 
levels of CXCR5 than B cells and comprised not more than 15% of all T cells. When 
comparing HD and SS patients, the total T cell population did not reveal any major 
differences. However, in the CXCR5-positive T-cell subset, decreased frequencies of Th17 
cells became apparent. Also, the frequency of TFH cells characterised by CXCR5 positivity 
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and high expression programmed death protein 1 (PD-1), were increased in four patients in 
our cohort. This increased frequency of TFH did not correlate with any of the clinical 
parameters, however the data, including histology, were limited. These findings are 
particularly interesting given the importance of TFH in autoantibody-positive autoimmune 
diseases and suspected Th17 cells contribution to SS.95 
For twelve patients in our cohort, CXCR5 genotype data were available, and grouping by 
genotype confirmed the association between the T risk allele and reduced CXCR5 expression 
on MZ B cells also in our patients. We speculate that taken together, these observations 
reflect the homing of CXCR5-positive B cells from the circulation to target organs in SS. In 
support of this idea, the levels of plasma CXCL13 reversely correlated with percentages of 
circulating CXCR5 positive B cells. 
Presence of focal lymphocytic infiltrates in the minor salivary glands is one of the criteria for 
SS. The foci are dominated by T cells, but also contain B cells, FDC, pDC and 
macrophages.126 CXCR5-CCL13 and CXCR4-CCL12 have been suggested as the major 
chemokine axes involved in the formation of the infiltrates.176  
To understand if the decrease in frequencies of circulating CXCR5-positive cells could result 
from homing to the target organ in SS, we assessed expression of CXCR5 in salivary gland 
tissue biopsies. Indeed, CXCR5 expression was strikingly higher in patients with SS than in 
sicca patients. 
In SS, the infiltrates may become chronically large, replacing substantial portions of 
glandular tissue, reminiscent of physiological lymphoid tissue organogenesis.177 In around a 
quarter of SS cases, structures resemble conventional GC are found, in which FDC are 
surrounded by proliferating B and T cells.8,126,178 Approximately half of the patients in our 
IHC cohort displayed GC. 
To summarize the findings in this paper, we observed enrichment of CXCR5-positive cells in 
the target organ in SS, elevated CXCR13 levels in plasma, and reduced frequencies of 
circulating CXCR5+ B cells which also had lower cell surface expression of CXCR5. We 
show that SNP located in the CXCR5 locus is associated with the decrease in CXCR5 
expression on circulating B cells. We postulate that the lower frequency of CXCR5 in 
circulating B cells most likely reflect their homing to the target organ although disease 
associated genotypes may also contribute. 
3.1.2 CXCR5-positive circulating T cells are a heterogenous population, and TFR cells 
are of interest in Sjögren’s syndrome (Paper II) 
Following the publication of Paper I, a letter was addressed to the editor by Válter R Fonseca 
and Luis Graca; “Contribution of Foxp3+ TFR cells to overall human blood CXCR5+ T 
cells”.179 Given the possibility to respond to the letter, we were intrigued by the suggestion 
from Fonseca and Graca that the circulating CXCR5-positive T helper cell population is 
heterogenous with an increase in frequency of a subset of T follicular regulatory (TFR) cells 
defined as CD4+CXCR5+FoxP3+ in SS, and developed our response into a short report. 
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We first aimed to replicate the finding of VR Fonseca and L Graca in our cohort described in 
Paper I. We first analysed CXCR5+FoxP3+CD25+ T cells to identify the whole TFR 
population. The frequency of FoxP3+CD25+ T cells among CXCR5+CD4+ T cells was 
augmented in SS patients confirming Fonseca´s study. However, the frequency of CXCR5+ T 
cells in FoxP3+CD25+CD4+ T cells was not different in SS patients and HD donors. This 
discrepancy might result from a dimmer signal from FoxP3, which would impact the 
FoxP3+CD25+ gate purity, thus defusing differences in the downstream population 
frequencies. Hence, using CXCR5 in a first gating step might provide a better resolution of 
TFR populations. 
The ratio between total TFH (CD4+CXCR5+) and TFR cells was increased in SS patients, 
confirming previous reports.180 Further, SS patients had higher frequencies of PD-1-positive 
TFR, suggesting, on one hand, an active state of these cells, and on the other, the effect of type 
I IFN, which is known to upregulate PD-1.181 
TFR were first characterized in 2011 as a subset of Treg cells functioning in lymphoid follicles 
and possessing hallmark transcription factors FoxP3 and BCL-6.99-101 A study from Miyara et 
al. revealed that the circulating Treg counterpart can be further sub-phenotyped into three 
fractions, according to FoxP3 and CD45RA expression.182 Fraction I cells (FoxP3lowCD45+) 
are considered naïve Treg, Fraction II (FoxP3highCD45-) effector Treg, and fraction III 
(FoxP3lowCD45-) are effector T cells.182 Applying this phenotyping approach to the CXCR5-
positive portion of Treg (i.e. TFR), did not reveal differences within fractions I, II and III 
between SS patients and HD. We however confirmed previous data showing that CXCR5-
positive Treg have an enriched naïve phenotype (Fraction I) suggesting that TFR are bona fide 
regulatory T cells.  
Together with elevated frequency of PD-1 expressing cells, these observations imply the 
unique properties of TFR as a new subset of circulating CXCR5-positive cells, underlining the 
importance of their sub-phenotyping in autoimmune diseases. The estimation of TFR 
frequencies in circulation is a relevant surrogate marker of autoantibody production activity 
in ectopic lymphoid tissue in RA183 and SS,180 however in SLE this correlation is not as 
strong. 103 
 
3.2 TRIM21/Ro52 in autoreactive and malignant B cells 
TRIM21/Ro52 first caught research attention as an autoantigen for Ro/SSA autoantibody. 
Ro/SSA and La/SSB were described in 1961 and started to be implemented into clinical 
practice in 1964.184 Later, for several autoimmune diseases the association between the 
autoantibody specificity and clinical features of disease was established.185 This supported the 
idea that autoantibodies might affect the functionality of their targets, and not just reflect 
autoreactivity in general and trigger inflammation. TRIM21 turned out to have a self-standing 
role in the immune regulation and in basic cellular processes. In Papers III and IV we aimed 
to expand the knowledge about this multifunctional protein. 
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3.2.1 Trim21 in B cells (Paper III) 
Ro52/TRIM21 is a main autoantigen in Sjögren’s syndrome and SLE. Interestingly, Trim21 
knock-out mice (Trim21-/-) develop systemic autoimmunity with B cell-related features 
including autoantibodies, hypergammaglobulinemia and glomerulonephritis after tissue 
injury, implying a potential role for Ro52/TRIM21 in the pathogenesis. Autoantibodies 
directed to Ro52/TRIM21 can inhibit its E3 ligase activity,41,186,187 and may thus potentially 
lead to a Ro52/TRIM21 deficient state in patients with Sjögren’s syndrome and SLE. To 
understand how Trim21 deficiency may contribute to B cell disturbances, we analyzed the B 
cell responses of Trim21-/- mice after immunization with T cell-dependent (OVA) and T cell-
independent (Ficoll, LPS) antigens. 
NP-OVA immunization yielded differences in antigen-specific IgM and IgG levels, with 
higher levels in Trim21-/- mice, as well as higher frequencies of NP-specific B cells (assessed 
by both flow cytometry and ELISPOT) and plasma cells. IgM and IgG levels were also 
higher in Trim21-/- mice immunized with NP-Ficoll. Both OVA and Ficoll act through the 
BcR, and one explanation of these data might be that Trim21 regulates signalling downstream 
of the BcR. Indeed, Trim21-/- B cells displayed higher proliferative response in vitro upon 
stimulation by BcR, which was observed by both [3H]-thymidine incorporation and Ki67 
staining. 
It may seem unexpected that NP-LPS immunization did not reveal differences in anti-NP 
antibody levels, since Trim21 has been suggested to act downstream of several TLRs.44,63,188 
However, LPS stimulation of Trim21–/– B cells in vitro has been previously shown to generate 
similar degree of IgM production as in wild type mice, consistent with our observations.63 
Flow cytometric analysis of splenocytes ex vivo revealed higher frequencies of follicular B 
cells in samples from NP-OVA-immunized Trim21–/– mice. While no difference in CD19+ 
cell frequency has been described in naïve mice earlier,44 we revisited the issue of B cell 
subpopulations in naïve Trim21–/– mice, and indeed observed an expansion of follicular B 
cells in both young and aged mice. To understand the differences between follicular B cells 
derived from Trim21–/– and Trim21+/+ mice, we sorted follicular B cells and subjected them to 
microarray analysis. 
Analysis of the microarray data revealed substantial differences between follicular B cells of 
Trim21–/– - and Trim21+/+ mice. Gene set enrichment analysis using Gene Ontology (GO) 
terms revealed the term “Regulation of B cell differentiation” as the most significant result. A 
shift towards follicular B cells might reflect a subtle immune-related process, for instance, 
due to presence of limited amounts of non-pathogenic microorganisms. The “Cell Cycle” GO 
term contains 1636 genes, and, despite significant results of ranked list enrichment test, 
seems more likely to reflect a high overlap with differentiation-related pathways than a 
genuine enrichment. 
Interestingly, among the differentially expressed genes (DEG), multiple entries were 
regulated by the sterol regulatory element-binding protein (SREBP) (data not shown). In 
relation to that, it is interesting to note that patients with SS are known to be at higher risk of 
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metabolic syndrome.113 Further, several metabolic disorders reveal underlying pro-
inflammatory mechanisms, e.g. macrophage and Th1 and Th17 activation. 
A limitation of this study is that is does not distinguish between the intrinsic and extrinsic 
effects of Trim21 deficiency on B cells. Some of the data described here might thus derive 
from influences from other cell types on B cell homeostasis and functions. 
In sum, we observed enhanced proliferation and antibody production in immunized mice and 
BcR stimulated cells. Our data from naïve mice are suggestive of Trim21 affecting B cell 
differentiation and, unexpectedly, sterol metabolism. Thus, Trim21 might play a slightly 
different role in non-stimulated B cell signalling. The anti-proliferative and anti-
differentiational effects of Trim21 might, at least partially, be explained by already described 
interactions of Trim21 within the NFκB50,189 pathway or/and ubiquitination of IRFs, though 
so far unidentified targets may also exist.  
3.2.2 TRIM21 in lymphoma (Paper IV) 
Anti-proliferative properties of TRIM21 have been demonstrated in several previous studies, 
including our Paper III,41,135,136 and higher expression level of TRIM21 has proven to be a 
marker of better prognosis in several types of tumours, but not in pancreatic cancer,137 where 
this association was reversed. In our studies of lymphoma, we questioned if maintained 
expression of TRIM21 is beneficial also for prognosis in diffuse large B-cell lymphoma 
(DLBCL) and autoimmunity-associated DLBCL. DLBCL is the most common B-cell 
lymphoma in both RA190 and SLE.191 
We show that survival parameters (overall and progression-free survival) positively correlate 
with TRIM21 expression in the tumour tissue, both in patients with and without autoimmune 
disease. We also confirm the anti-proliferative effect of TRIM21 in human ex vivo PBMC. 
In our cohort of patients with autoimmune diseases, most patients were diagnosed with RA, 
and one third with SLE. The risk of DLBCL in RA is approximately two times higher than 
that in the general population,192 and it correlates with RA disease activity.193 The prognosis 
is worse than in DLBCL in non-autoimmune patients, most likely due to the higher 
prevalence of the ABC type of lymphoma. SLE and a subset of RA patients are characterized 
by an IFN signature, and TRIM21 is an IFN-stimulated gene. One could thus expect higher 
TRIM21 expression in autoimmunity cohort. Surprisingly, we observed the opposite: 42% of 
patients fell into the TRIM21 low subgroup (versus 12% and 20% in the other two cohorts), 
although these data are consistent with the worse prognosis.  
In accordance with previous studies,193 in the cohort of lymphoma patients with 
autoimmunity, there was a shift towards ABC subtype (67%). IRF4, one of the hallmark 
molecules for ABC DLBCL,117 is known to downregulate TRIM21,43 which could contribute 
to the IFN-TRIM21 discrepancy. At the same time, there was no correlation between DLBCL 
subtype and TRIM21 expression in any of the cohorts, indicating the importance of other 
mechanisms. For instance, lower TRIM21 expression might give the cells a proliferative 
advantage, thus the amount of those would increase with disease (lymphoma) duration. 
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Therefore, we concluded that TRIM21 might have an independent prediction value in both 
autoimmunity-related and self-standing DLBCL. 
One mechanism of tumour suppression by TRIM21 might be restriction of proliferation, as 
illustrated by the pokeweed mitogen experiment included in this study, as well as data from 
Paper III, where mouse Trim21–/– splenocytes displayed enhanced proliferation upon BcR 
stimulation. Another potential contributor might be activation-induced apoptosis (AIA). 
Indeed, exogenous expression of Trim21 made a mouse lymphoma A20 susceptible to CD40-
induced apoptosis.41 Burington et al. investigated the signalling behind AIA in DLBCL and 
concluded that it was mediated by p53, and that expression of BCL-6 and high degree of 
DNA damage increased susceptibility to AIA.132 If this hypothesis holds true, maintained 
TRIM21 expression could be an indication of administration of anti-CD40 monoclonal 
antibodies, e.g. Dacetuzumab, to patients with DLBCL. 
3.2.3 Identifying the TRIM21 interactome using proximity labelling by BioID2 
Multiple substrates for TRIM21-mediated ubiquitination have been described. However, a 
picture of TRIM21 interactions remains fragmentary. We have recently initiated a project to 
assess the interactome of TRIM21 using proximity labelling with biotin followed by mass 
spectrometry. I have chosen to include data from the project here, although a full manuscript 
has not been generated. Two advantages of proximity labelling compared to e.g. 
immunoprecipitation are the more robust capture and an opportunity to track the interactors 
within a desired time frame and proximity (reviewed in194). BioID2 is a modified biotinylase 
from E.coli (BirA),195 capable of labelling the adjacent proteins in a non-specific fashion. The 
technique includes introduction of the protein of interest, fused to BioID2 by a linker 
sequence, to the model cells. Cells are exposed to biotin, harvested, and the cell lysates are 
subjected to mass spectrometry for identification and quantification of the biotinylated 
proteins. 
Plasmid generation and A375 transduction 
The TRIM21 cDNA sequence with a N-terminal GGGGS linker was cloned into a pBABE-
Myc-BioID2 plasmid (Addgene) by digesting with XhoI and SalI and ligation with T4 ligase. 
The plasmid was extracted from the gel and propagated in Endura Competent Cells (Lucigen) 
using electroporation and subsequent ampicillin selection. The plasmid was purified with 
NucleoBond Xtra Midi kit (Macherey-Nagel). The success of cloning was verified by 
digestion with XhoI and SalI (Fig 1A) and by sequencing. The expression of Myc-BioID2-
TRIM21 fusion protein was verified by western blotting of transfected HEK293T cell lysate 
with the anti-TRIM21 antibody (Fig 1B). Next, HEK293T cells were transfected with 
pBABE-Myc-BioID2 with and without TRIM21, pUMCV and pMD2.G plasmids (Addgene) 
and X-tremeGENE 9 (Roche) to generate the retroviral vectors: 
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The virus-containing supernatants were used to transduce A375 cells. The transduced clones 
were selected with 1ug/ml Puromycin and expanded. We then exposed the cells to 50uM 
biotin for 20h before lysis and performed western blot using HRP-conjugated streptavidin 
(Fig 1C). 
 
Figure 1. Main steps of TRIM21 proximity labelling experiment (A) TRIM21 cloning. pEX-k248-
T21, source plasmid; U, undigested; D, digested with SalI and XhoI. (B) Transitional expression of 
Myc-BioID2-TRIM21 plasmid in HEK293T cells, mouse anti-human antibody against TRIM21, 
HRP-conjugated secondary antibody. Untr, untransfected. (C) Biotinylation in transduced A375 cells 
after incubation with 50uM biotin for 20h. (D) Abundance ratios of LC-MS hits, n = 730. (E) 
Overrepresentation analysis, by Enrichr tool, Reactome library. All depicted overlaps are significant 
(p=3.7^10-9 and lower); the colour intensity is proportional to significance. Combined scores are 
resultant of three enrichment analysis methods suggested by Chen EY et al;196 AR, abundance ratio. 
Stable isotope labelling of proteins and Mass Spectrometry 
Once the BioID2 biotinylating capability was confirmed, the cells were cultured for one week 
with Stable isotope labelling by amino acids in cell culture (SILAC) medium (ThermoFisher 
Scientific). A375 cells transduced with Myc-BioID2-TRIM21 were cultured with medium 
supplemented with stable isotope-containing (heavy) 13C6 15N2 L-lysine-2HCl and 13C6 15N4 
L-arginine-HCl, and control cells were cultured with light (naturally prevalent) amino acids. 
Cells were then harvested for protein extraction, as described by in197,198. The concentrations 
of proteins in “heavy” and “light” samples were equalized, and the lysates were merged. The 
purification of biotinylated proteins was performed using streptavidin-coated magnetic beads. 
The resulting bead suspension contained TRIM21 interactome proteins, labelled with heavy 
amino acids and a control “non-specific” interactome proteins of BioID2, composed of light 
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amino acids. Liquid chromatography - mass spectrometry (LC-MS) was performed after on-
bead trypsinization. 
Data analysis 
The set of identified proteins generated using Mascot software was obtained from Proteomics 
Biomedicum Facility, Karolinska Institutet. Only characterized master protein entries were 
used for further analysis. We first ran the protein ID list through the Contaminant Repository 
for Affinity Purification (CRAPome),197 to remove background contaminants. CRAPome 
score less than 50 was used as a threshold. The heavy to light protein abundance ratios (AR) 
were log2 transformed. 
TRIM21 interactors 
Filtering as described above yielded a list of 900 entries. The entries with log2 AR between -
2 and 2 were considered background noise and removed, resulting in 730 hits (Fig 1D) for 
running an overrepresentation analysis using the Enrichr tool,196,199 Reactome library. The 
terms with significant overlap with our data are illustrated by Fig 1E. 
The two Reactome terms with the highest degree of overlap with our dataset were Cell Cycle 
(R-HSA-1640170) and Transcriptional Regulation by TP53 (R-HSA-3700989), which goes 
in line with previous findings, including the ones in Papers III and IV. The vesicular 
trafficking-related terms were identified also in anti-Ro/LA-positive mothers from our 
neonatal lupus study (Paper V). TRIM21 is upregulated in SS and SLE, and our 
experimental conditions here might mimic that due to additional (exogenous) TRIM21 
expression.  
Interestingly, several protein hits in our study have been previously described as TRIM21 
interactors. Out of 116 unique TRIM21 interactors listed at BioGRID 
(https://thebiogrid.org/112615/summary/homo-sapiens/trim21.html), 11 (TRIM21, RC3H1, 
CBL, HAUS2, JUNB, MNAT1, NCOA3, PAWR, SPDL1, ZNF598, SQSTM1) were present 
in our dataset (n=730). Other interesting entries included IFNAR2, NFκB1, RELA, STAT3, 
adaptor of cytosolic RNA sensors MAVS, autoantigens PML and SP-100 and many more 
(Fig 1D). 
However, a majority of proteins was only present in the control sample, most likely due to 
TRIM21-specific ubiquitination and (at least partial) degradation in Myc-BioID2-TRIM21-
tranduced (“heavy”) cells. Thus, both genuine TRIM21 substrates and non-specifically 
biotinylated proteins would gain high abundance in the control sample. Unfortunately, our 
current experiment design does not allow distinguishing between them. To circumvent this 
issue, we are planning to repeat the experiment using a mutated version of TRIM21. 
Removing the critical catalytic cysteine from the RING domain will result in abolished 
ubiquitination capacity.200 As a result, MS hits with lower abundance in the cells transduced 
with functional Myc-BioID2-TRIM21 (“heavy”) sample should reveal genuine substrates of 
TRIM21-mediated ubiquitination. 
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3.3 Congenital heart block 
Another comorbidity in SS and SLE, congenital heart block (CHB) is a rare, but dangerous 
condition, dictating a need for further research in order to create effective therapeutic and 
preventive management strategies. The peculiar feature of CHB is a location- and time- 
specific inflammatory process in the foetus, induced by maternal antibodies that do not affect 
the maternal heart. Despite a sustained effort, the fetal autoantigen in CHB has not been 
definitively identified, highlighting the complexity of CHB pathogenesis. Thus, in papers V 
and VI we chose to approach the problem from a different perspective and focused on the 
factors of fetal/neonatal immunity. 
3.3.1 Type I IFN in newborns exposed to autoantibodies against Ro and La (Paper V) 
Autoantibodies against Ro and La can induce production of type I IFN in PMBC and pDC, 
which has been suggested as the central mechanism for generation of the IFNα found in 
patients with SS and SLE, and for the subsequent upregulation of IFN stimulated genes.201,202 
During pregnancy, maternal IgG, including autoantibodies of IgG class is transported across 
placenta. The foetus of the mothers carrying anti-Ro/La autoantibodies is at risk of neonatal 
lupus erythematosus (NLE) including a congenital heart block (CHB). The pathogenic 
mechanism is not well understood, and while many attempts have been made to identify fetal 
targets for the autoantibodies, the question whether the antibodies may induce an activation 
of the IFN system also in the foetus has not been addressed. In this study we therefore aimed 
to characterize type I IFN activation in newborns antenatally exposed to maternal anti-Ro/La 
autoantibodies. 
To address the question if the neonates born to anti-Ro/La positive mothers differ in their 
gene expression from neonates born to heathy donors (HD) we analysed the gene signatures 
from PBMC of mother-baby pairs. Gene enrichment analysis revealed Gene Ontology (GO) 
terms related to type I IFN and anti-viral response in both anti-Ro/La positive mothers and 
anti-Ro/La exposed neonates when compared to HD mothers and neonates, correspondingly. 
We next performed a DELFIA assay203 to measured IFN levels, and in anti-Ro/La positive 
subjects (both mothers and their newborns) they were significantly elevated, confirming our 
microarray findings. 
Interestingly, the third set of GO terms differed between anti-Ro/La exposed mothers and 
their neonates. In the neonates, GO:0034341 Response to interferon gamma was identified 
(investigated in more detail in Paper VI), while in the mothers, vesicle-related process was 
revealed. 
Interesting hits among maternal differentially expressed genes (DEG) include IRF7, a 
transcription factor downstream of TLR9 and a target for TRIM21-mediated 
ubiquitination,43,44 and TNIP1, a susceptibility gene for SS, SLE and RA58,204,205 and a part of 
the NFκB pathway. In anti-Ro/La-exposed neonates, TGFB1, a multifunctional and potent 
cytokine was upregulated.206 
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The presence of type I IFN was further confirmed by calculating an IFN score, a value 
derived from accumulated normalized expression of selected IFN-regulated genes. IFN 
scores were significantly higher in both mothers and neonates exposed to autoantibodies and, 
moreover, highly correlated with each other. Interestingly, the subgroup of neonates of 
mothers treated with immunomodulatory drugs, such as hydroxychloroquine (HCQ) and 
azathioprine, had significantly lower IFN score than the non-treated subgroup, while maternal 
IFN scores were equally high to the non-treated group. HCQ, a drug widely administered 
during pregnancy to patients with SS, SLE and other autoimmune diseases,8,207 is a basic 
lipophilic substance with a capacity to accumulate in lysosomes and endosomes, thus 
increasing their internal pH.208 This renders the conditions for TLR triggering suboptimal, 
and thus interrupts induction of type I IFN production in pDC. HCQ is known to cross 
placenta, hence, the observed decrease in type I IFN score in treated neonates might be 
explained by effect of HCQ on neonatal pDC. 
Next, we visualized microarray expression data separately for Regulation of type I IFN 
production and Response to type I IFN Gene Ontology terms and observed an activation of 
both processes. These data suggested that type I IFN in anti-Ro/La-exposed neonates could 
originate from their own cells. It has previously been shown that adult immune cells can 
produce type I IFN after exposure to anti-Ro/La antibodies combined with apoptotic/necrotic 
material, but whether fetal immune cells also have that ability was not known. We tested this 
in vitro by stimulating neonatal cells with anti-Ro/La positive serum together with necrotic 
material and confirmed for the first time the capacity of neonatal PBMC to produce IFN. 
Finally, as a confirmation of downstream type I IFN activity at the protein level, the 
expression of the lectin Siglec-1 (sialoadhesin, CD169) on monocytes in both anti-Ro/La 
exposed mothers and neonates was strikingly higher than that of healthy donors. Siglec-1 was 
previously suggested as a convenient flow cytometry marker to monitor maternal type I IFN 
status throughout pregnancy.209 
While IgG transfer is dependent on FcRn,210 a vast diversity of substances is delivered 
through placenta by extracellular vesicles. Earlier studies suggest the IFN does not cross term 
placenta.211 However, placenta-derived extracellular vesicles were recently shown to contain 
multiple chemokines, growth factors and cytokines, including IFN, IFN, IFN and 
TGF.212 Considering the mode of action of HCQ, one might hypothesize that, except for a 
direct effect on neonatal IFN production through TLR, HCQ could alter maternally-derived 
cytokine influx by modifying vesicular transport. Indeed, chloroquine, belonging to the same 
family of drugs as HCQ, was shown to block exosome internalization in microglia.213 It is 
tempting to speculate that a vesicle-related process occurring in anti-Ro/La-positive mothers, 
as indicated by our microarray data, is related to active transfer of cytokines to the foetus. 
This could be a conserved mechanism developed to supply the foetus with protective 
substances if a viral infection is sensed in the mother. The origin of type I IFN in the foetus 
remains to be fully established, and transfer from the mother and production in the foetus are 
not mutually exclusive possibilities. 
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Here we show that neonates exposed to maternal Ro and La autoantibodies in utero, alike 
their mothers, have elevated levels of type I IFN, accompanied by type I IFN signature at 
mRNA and protein level. Our data indicate that neonatal cells are capable and active as IFN 
producers, suggesting a probable fetal origin of the cytokine. 
3.3.2 Cord blood cell profiling in newborns at risk of CHB (Paper VI) 
The association of anti-Ro/La autoantibodies with neonatal lupus and congenital heart block 
(CHB) is well known, and the serology of the mothers and babies has been extensively 
investigated.140,214 The immune cell profile in peripheral blood of non-pregnant women with 
anti-Ro/La autoantibodies has also been described, however that of pregnant women with 
anti-Ro/La autoantibodies is less well known. Similarly, the cord blood cell characteristics of 
newborns under risk of CHB have not been studied. In Paper VI, we therefore described the 
circulating immune cells in anti-Ro/La positive mothers and their newborns. 
We first screened maternal and neonatal major blood cell populations. In the mothers, we 
observed deviations in B and T cell frequencies, as previously described for patients with 
systemic autoimmunity. In the anti-Ro/La-exposed neonates, T and B lymphocyte prevalence 
did not differ from those of healthy donor (HD) neonates, however, higher frequencies of 
NK/NKT cells were observed. In anti-Ro/La-exposed newborns of mothers receiving 
immunomodulatory treatment, this difference was no longer present. 
To confirm our cellular findings in anti-Ro/La-exposed newborns, we performed gene 
enrichment analysis of microarray data from the same cohort. Indeed, two libraries from 
“Cell types” category of Enrichr Tool196,199 yielded significant overlap between our DEG set 
and NK-cell-related terms. Interestingly, in both libraries, the second most significant overlap 
was with plasmacytoid dendritic cell terms. This finding goes in line with the elevated levels 
of IFN from Paper V. 
We next tested if the levels of type II IFN were also elevated as this is the main cytokine 
produced by NK cells. Although the difference did not reach significance, some of the anti-
Ro/La-exposed neonates had high levels of IFN, while in all HD, but one, the IFN was 
virtually absent. Moreover, NK cell frequencies and INF concentrations correlated (Fig 2), 
suggesting that neonatal NK cells might be the source of the cytokine.  
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Figure 2. Correlation between NK/NKT cell frequencies and IFN levels in anti-Ro/La-exposed 
and healthy newborns. Spearman’s rank correlation coefficient. Data from neonates from families 4 
and 9 (HD) and anti-Ro/La-exposed subjects from families 11, 12, 18 and 23. Data from a treated 
subject (family 23) is illustrated as an open triangle. r = 0.89, p < 0.03. 
The presence of IFN was further illustrated by an IFN score, which was calculated the same 
way as described for the type I IFN score,215 but using genes preferentially regulated by type 
II IFN. Finally, to attempt to dissect type I and type II signatures, we applied a modular 
analysis suggested by Chiche et al. All three modules exhibited significant HGT results, 
however, the p values gradually increased from module M1.2 (representing type I IFN 
signature) to M5.12 (representing type II IFN signature). The unsupervised hierarchical 
clustering followed the same trend. This was not surprising, considering not all anti-Ro/La 
exposed individuals had detectable IFN in the plasma. Finally, we observed upregulation of 
HLA-DR on monocytes of anti-Ro/La exposed newborns, reflecting the presence of IFN 
(predominantly IFN). With these indications of a role of NK cells in pathologies following 
anti-Ro/SSA exposure, we sought to understand if they could contribute to the cardiac 
inflammation in CHB. Indeed, even a short-term stimulation of cardiomyocytes with type I 
IFN yielded upregulation of chemoattractants and activating ligands for NK cells. 
Our findings are suggestive of IFN and NK cells involvement in NLE, however, the data 
may be interpreted ambiguously. A subset of SS and SLE patients have increased IFN 
levels, but there is no consensus on its clinical meaning, association with disease activity or 
increased risk of lymphoma.38,216,217 NK cells have been shown to infiltrate adult heart tissues 
in multiple cardiac inflammatory diseases and even initiate the inflammatory process in viral 
myocarditis (by secretion of all three types of IFN and IL-12), however, their functions vary 
from directly cytotoxic to immunosuppressive and often are combined within the same 
pathology.218 Besides, the properties of neonatal NK cells might differ from those of the 
adult. Rival et al. describe a mouse model of autoimmune ovarian disease in the neonate 
induced by maternal zona pellucida 3 autoantibody, which was mediated by neonatal, but not 
maternal, NK cells. The difference was explained by a lack of expression of inhibitory 
receptor Ly49 on neonatal NK cells.219 In a mass cytometry study, Strauss-Albee et al. 
revealed no major differences between adult and cord blood NK cells, yet IFN and TNF 
production, as well as ADCC and target apoptosis induction were significantly reduced in 
neonatal cells.220 
Taken together, our findings indicate involvement of the innate branch of immunity in anti-
Ro/La exposure-related pathologies, potentially mediated by an interplay of pDC and NK 
cells. 
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4 CONCLUDING REMARKS AND FUTURE RESEARCH 
QUESTIONS 
 
This thesis addressed cellular and molecular factors in the pathogenesis of systemic 
autoimmunity and comorbidities.  
The three main themes of our studies reveal: 
- A decrease of CXCR5 expression in circulating B cells in patients with Sjögren’s syndrome. 
This might be explained by the homing of B cells with high cell surface expression of 
CXCR5 to the autoimmune target organs exocrine glands. Genetic polymorphisms of CXCR5 
may also contribute to differential B cell trafficking. The frequency of the TFR cell population 
is altered in SS, and might be useful as marker of inflammation activity. 
- TRIM21/Ro52, an autoantigen in SS and SLE, affects B cell antibody production, 
proliferation, and, presumably, differentiation decisions. Higher TRIM21 expression in 
tumour cells is associated with better prognosis in diffuse large B-cell lymphoma. 
- Cord blood cells from neonates exposed to maternal anti-Ro/La autoantibodies display signs 
of type I and type II IFN activity and are capable of IFN production. NK cells and pDC 
supposedly contribute to the immune activation in these subjects. Both elevated type I IFN 
scores and NK cell frequencies in the neonates are affected by maternal immunomodulatory 
treatment. 
 
The future questions appearing most relevant from a scientific and clinical point of view 
are: 
- What are the mechanistic effects of the SS-associated CXCR5 gene locus SNP? 
- Is TRIM21 involved in activation-induced apoptosis in B-cell lymphoma? Can it be used as 
a predictor of sensitivity to therapy with anti-CD40 monoclonal antibodies? 
- What are the roles of NK cells and IFN in cardiac inflammation in congenital heart block? 
Which yet unknown ways does HCQ impact immune activation in anti-Ro/La exposure in 
utero? 
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